Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis
Journal of Pharmacy and Pharmacology · 2023
DOI: 10.1093/jpp/rgad055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Ammar Sarwar und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, PR China. Hauptthemen laut MEDLINE: MicroRNAs, Pancreatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shaanxi Province Science Fund for Distinguished Young Scholars, Shaanxi Province Science and Technology Development Plan Project.
Abstract (Originalsprache)
Objectives
Pancreatic cancer (PC) is a very lethal malignancy with a scarcity of treatment options. Although erlotinib- and gemcitabine-based treatments have been approved for PC, their effectiveness is limited. The present study is aimed at exploring the molecular and epigenetic mechanisms of anticancer activities of homoharringtonine (HHT) and its interaction with erlotinib to develop a potential therapeutic strategy for PC.
Methods
The RT-qPCR, western blotting, immunofluorescence and expression-vectors and oligonucleotide transfection were employed to determine the expression characteristics of onco-factors. Anticancer activities were determined by MTT, colony forming, and flowcytometric analysis. Dual luciferase assay was conducted to confirm putative target of miR-130b-3p. In-vivo experiments were followed by immunohistochemical assay. Key findings The EphB4/JAK2/STAT3 pathway drives the growth and proliferation of PC through induction of prosurvival factors and cell cycle mediators. HHT directly and epigenetically via miR-130b-3p targets EphB4, leading to downregulation of JAK2/STAT3 pathway. The inactivation of STAT3 results in diminution of antiapoptotic factors and cell cycle mediators. HHT also enhances the anticancer activity of erlotinib.
Conclusions
HHT demonstrates potential anticancer activities in PC by downregulating EphB4/JAK2/STAT3 signalling. HHT also produces synergistic effects with erlotinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, PR China.
- Institute of Pharmaceutical Sciences, University of Veterinary & Animal Sciences, Lahore, Pakistan.
- State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an Jiaotong University, Xi'an, PR China.
ORCID-Profile: Ammar Sarwar, Yanmin Zhang
Förderung
- National Natural Science Foundation of China
- Shaanxi Province Science Fund for Distinguished Young Scholars
- Shaanxi Province Science and Technology Development Plan Project
- Project of Shaanxi Provincial Administration of Traditional Chinese Medicine
- Shaanxi Buchang Pharmaceutical
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Sarwar, A., Zhu, Z., Zhu, M., Tang, X., Su, Q., Yang, T., Tang, W., & Zhang, Y. (2023). Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad055
Vancouver
Sarwar A, Zhu Z, Zhu M, Tang X, Su Q, Yang T, et al. Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad055
BibTeX
@article{Sarwar2023,
author = {Sarwar, Ammar and Zhu, Zeren and Zhu, Man and Tang, Xiaoyu and Su, Qi and Yang, Tianfeng and Tang, Wenjun and Zhang, Yanmin},
title = {Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis},
journal = {Journal of Pharmacy and Pharmacology},
year = {2023},
doi = {10.1093/jpp/rgad055}
}
EUVIMED